Skip to main content
. Author manuscript; available in PMC: 2012 Oct 3.
Published in final edited form as: Expert Rev Vaccines. 2011 Jun;10(6):743–753. doi: 10.1586/erv.11.70

Table 1.

In 2 phase III trials, sipuleucel-T demonstrated an overall survival advantage relative to placebo.

Population n Results Ref #
Metastatic castration-
resistant prostate cancer		 127 (82 on
treatment, 45 on
placebo)		 Overall survival favored the
treatment arm: 25.9 months vs.
21.4 months (P = 0.01, HR =
1.45).		 14
Metastatic castration-
resistant prostate cancer		 512 (341 on
treatment, 171
on placebo)		 Overall survival favored the
treatment arm: 25.8 months vs.
21.7 months (P = 0.032, HR =
0.78).		 17